Objectives To describe the treatment patterns and determine the effectiveness and safety of
nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan …

Introduction Nivolumab has been shown to be effective and safe in previously treated
patients with advanced non-small cell lung cancer (NSCLC). However, little is known …

Objective Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint
inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer …

Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …

Background Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for
previously treated advanced non–small-cell lung cancer based on the results from phase III …

Objectives Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was
no dose–response/toxicity relationship of nivolumab. This study evaluated the efficacy of low …

Objectives To investigate the efficacy and safety of nivolumab in Korean patients with stage
IIIB/IV or recurrent non-small-cell lung cancer (NSCLC) who failed platinum-based …

Background: Nivolumab has shown promising effects in patients with non-small-cell lung
cancer (NSCLC) as a second-or later-line treatment. This study aimed to identify patients …

Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open …

Postmarketing surveillance of Japanese patients with unresectable, previously treated,
advanced or recurrent non‐small‐cell lung cancer treated with nivolumab was undertaken …